RESEARCH ARTICLE

Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma — a retrospective interventional case series [version 1; peer review: 1 approved, 1 approved with reservations]

Piotr Strzalkowski, Alicja Strzalkowska, Winfried Göbel, Nils A. Loewen , Jost Hillenkamp

Department of Ophthalmology, School of Medicine, University Hospital Wuerzburg, 97080, Germany

V1 First published: 14 Oct 2020, 9:1236
<https://doi.org/10.12688/f1000research.26879.1>
 Latest published: 02 Mar 2021, 9:1236
<https://doi.org/10.12688/f1000research.26879.2>

Abstract

Background: Neovascular glaucoma (NVG) is a severe, potentially blinding disease and a therapeutic challenge. The purpose of this study was to evaluate the safety and efficacy of an integrative surgical approach to neovascular glaucoma.

Methods: Retrospective analysis of a one-year follow-up of a consecutive interventional case series of NVG. Eyes underwent transscleral cyclophotocoagulation, pars plana vitrectomy, near-confluent panretinal photocoagulation, and intravitreal bevacizumab. Phakic eyes underwent concomitant cataract surgery. Best-corrected visual acuity (BCVA, logMAR), intraocular pressure (IOP, mmHg), number of glaucoma medication, visual analog pain scale (VAPS, 0-10) were recorded at baseline, and 1, 3, 6, and 12 months. Blind eyes were excluded.

Results: Seventy-seven eyes of 77 patients (45 male, 32 female, mean age 73.6±12.2 years) were included. NVG underlying conditions included retinal vein occlusion (41.6%), proliferative diabetic retinopathy (35.1%), central retinal artery occlusion (19.5%), and ocular ischemic syndrome (3.9%). Mean IOP decreased postoperatively from 46.3±10.1 mmHg to 14.5±7.9 mmHg ($p<0.001$), glaucoma medication from 4.7±1.3 to 1.8±1.8 ($p<0.001$), and VAPS from 6.0±1.8 to 0. BCVA remained unchanged. Postoperative intraocular inflammation had resolved in all eyes at the one-month follow-up. 71.4% (55/77) eyes did not require additional major interventions during follow-up.

Conclusions: A single, comprehensive surgery session lowered IOP significantly, reduced GMS, and controlled pain.

Open Peer Review

Approval Status

	1	2
version 2		
(revision)
02 Mar 2021	view

version 1
14 Oct 2020	view	view

1. **Andrew W. Eller**, University of Pittsburgh Medical Center (UPMC), Pittsburgh, USA

Saloni Kapoor , University of Pittsburgh Medical Center, Pittsburgh, USA

2. **Stefan Dithmar**, HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany

Any reports and responses or comments on the article can be found at the end of the article.

Keywords

Neovascular glaucoma, integrative surgical approach, iris neovascularization

This article is included in the **Eye Health** gateway.

Corresponding author: Piotr Strzalkowski (strzalkows_p@ukw.de)

Author roles: **Strzalkowski P:** Conceptualization, Data Curation, Investigation, Methodology, Writing – Original Draft Preparation; **Strzalkowska A:** Data Curation, Investigation, Methodology, Writing – Original Draft Preparation; **Göbel W:** Writing – Review & Editing; **Loewen NA:** Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Hillenkamp J:** Methodology, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Strzalkowski P *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Strzalkowski P, Strzalkowska A, Göbel W *et al.* **Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma — a retrospective interventional case series [version 1; peer review: 1 approved, 1 approved with reservations]** F1000Research 2020, 9:1236 <https://doi.org/10.12688/f1000research.26879.1>

First published: 14 Oct 2020, 9:1236 <https://doi.org/10.12688/f1000research.26879.1>

Introduction

Neovascular glaucoma (NVG) is a serious complication of a variety of ocular and systemic conditions. Neovascularization is the formation of abnormal blood vessels in an abnormal location triggered by an imbalance of anti-angiogenic and proangiogenic factors caused by retinal ischemia¹. NVG accounts for 3.9 to 9.2% of all new glaucoma diagnoses^{2–4}. According to the Federal Statistical Office of Germany, NVG's age-specific incidence in Germany in the age group from 45 to 64 years is 8 per 100,000. It increases to 24 per 100,000 in subjects older than 64 years⁵. The incidence of NVG varies depending on the etiology of retinal ischemia. For central retinal vein occlusion (CRVO) the reported incidence is 16%⁶, for proliferative diabetic retinopathy (PDR) 21.3%⁷, for central retinal artery occlusion (CRAO) 14.5%⁸, and ocular ischemic syndrome (OIS) 12.9%⁹, respectively. Carotid artery obstructive disease and fistulas are additional, extraocular vascular causes of retinal ischemia¹⁰. Early recognition and treatment of NVG are imperative to prevent aggressive evolution with severe vision loss and intractable pain that can require enucleation within a few months¹¹. NVG also carries a poor prognosis for general health: remarkably, the expected lifespan of patients with NVG decreased by 52% compared to an age-correlated normal population, which corresponds to 6.5 years. In diabetics with NVG, the expected lifespan was reduced even more significantly by 72% (5.1 years in this subgroup)¹².

In 1994, Miller *et al.* showed that retinal laser coagulation of primates could lead to CRVO and subsequent retinal ischemia with iris neovascularization¹³. In this model, neovascularization was mediated by vascular endothelial growth factor (VEGF) and correlated to its concentration. Several members of the VEGF family have since been identified, including VEGFA, VEGFB, VEGFC, VEGFD, and the placental growth factor (PLGF) with specific receptor-binding patterns. VEGFA primarily binds to VEGFR2, the activation of which stimulates neovascularization, relevant to NVG, and angiogenesis, the formation of normal blood vessels in normal development. In the eye, VEGF-A is produced by the retinal pigment epithelium, retinal ganglion cells, astrocytes, the endothelium, photoreceptors, and Müller cells^{14–17}. Retinal hypoxia upregulates VEGF primarily via the hypoxia-inducible factor (HIF-1 α and HIF-2 α). The concentration of HIF increases when hydroxylases are inhibited during hypoxia so that HIF is not degraded by the proteasome¹⁸. HIF binds to the hypoxia-responsive element (HRE) of the VEGF gene in the nucleus leading to its upregulation¹⁹.

Although the mechanism by which NVG emerges is hence relatively well understood, there is no consensus on how to best initiate treatment to address the different aspects. Treatment steps include lowering of IOP (topical and systemic glaucoma medications, glaucoma drainage implants, cyclodestruction)^{20–24}, anti-inflammatory treatment (topical or intraocular steroids), reduction of retinal ischemia (panretinal photocoagulation (PRP))^{25,26}, and inhibition of VEGF^{27–29}. Vitrectomy with PRP and silicone oil tamponade may also reduce IOP in eyes with NVG^{30,31}.

Here, we evaluated the safety and efficacy of an integrative combined surgical approach for evolving NVG that combined

pars plana vitrectomy, near-confluent full-scatter panretinal photocoagulation, off-label use of intravitreal bevacizumab, and transscleral cyclophotocoagulation in a single surgical session. We hypothesized that such a combined surgical approach for NVG would reduce IOP, medication, pain, reduce the number of necessary outpatient visits, and prevent the necessity of further surgeries.

Methods

Ethical statement

Our retrospective study was reviewed and approved by the Ethics Committee of the University of Würzburg (reference: 9/17-sc, dated February 3, 2017) and a clearance certificate for retrospective data evaluation was issued (reference: 20180108 02, dated January 30, 2018). For retrospective anonymized data analysis, patient's consent was not necessary. The Declaration of Helsinki, the Good Clinical Practice (GCP) guidelines and applicable data protection regulations were complied with.

Study design

We included all patients between October 2014 and August 2019 with NVG who met the inclusion criteria in this consecutive interventional case series.

Inclusion criteria were: 1) neovascularization of iris (NVI) or neovascularization of the angle (NVA), 2) IOP > 21 mmHg, 3) best-corrected visual acuity (BCVA, logMAR) $\geq$ light perception, and 4) 18 years or older.

All patients were treated at the University Eye Hospital in Würzburg, Germany. The combined intervention was part of routine patient care at our clinic and all patients with decompensated neovascular glaucoma and preserved visual function received this intervention. BCVA, intraocular pressure (IOP, mmHg), the number of glaucoma medication, visual analog pain scale (VAPS, 0–10) was recorded at baseline and at follow-up visits at one, three, six, and 12 months as part of routine care. Iris and anterior chamber neovascularization were graded using the Weiss and Gold rubeosis grading system³². Hypotony was defined as IOP $\leq$ 5 mmHg with hypotonous maculopathy, choroidal folds, or optic neuropathy³³. Phthisis bulbi³⁴ was defined as IOP $\leq$ 5 mmHg in a shrunken eye with worse than hand motion vision with or without pain containing atrophic and disorganized intraocular structures. Success was defined as IOP $\leq$ 21 mmHg or IOP reduction $\geq$ 30% from baseline, with or without glaucoma medication and without vision loss³⁵.

All patients underwent decimal visual acuity testing, which was converted to a logMAR scale. Counting fingers (CF), hand movements (HM), light perception (LP), and no light perception (NLP) were converted into logMAR units 1.9, 2.3, 2.7, and 3.0, respectively³⁶.

We retrospectively analyzed all patients treated with neovascular glaucoma at our clinic via the electronic hospital information system SAP®. The medical records of the treated patients were analyzed individually. The initial diagnosis of neovascular glaucoma and hospitalization served as the starting point. The cardiovascular risks were taken from the anesthesia premedication form.

Patient treatment and follow-up

Surgical technique. All eyes underwent transscleral cyclophotocoagulation (810 nm diode laser, 360 degrees treatment to pop threshold with 20 spots and leaving out 3 and 9 o'clock), standard 3-port 23 gauge pars plana vitrectomy with a detachment of the posterior vitreous if not already present, near-confluent full-scatter panretinal photocoagulation (PRP) applied under indentation in all four quadrants from the vascular arcades to the ora serrata, intravitreal application of 0.1 mL of bevacizumab (Avastin® 25 mg/1 mL, Roche Pharma, Switzerland), and air tamponade. Phakic eyes underwent concomitant cataract surgery. The operation was carried out either with a retrobulbar block or general anesthesia.

Retreatment. At follow-up, all eyes with elevated IOP were treated following an escalation scheme. First, glaucoma medications were increased to what was maximally tolerated. Eyes were then treated with transscleral cyclophotocoagulation (810 nm diode laser, 360 degrees treatment to pop threshold with 20 spots). Eyes that failed to respond to cyclophotocoagulation with a significant IOP reduction and had retained ambulatory visual acuity underwent tube shunt surgery. Repeated vitrectomy, including fill-in PRP, transscleral cyclophotocoagulation, and off-label use of intravitreal bevacizumab was applied to eyes with elevated IOP and dense vitreous hemorrhage. Fill-in PRP was applied when PRP could not be completed during surgery in eyes with extensive intraretinal hemorrhage. Further intravitreal injections of VEGF inhibitors were only applied for clinically significant non-ischemic macular edema and BCVA ≥ 1.1 logMAR.

Patients lost to follow-up. All patients who failed to attend follow-up visits completed a standardized telephone survey that contained the following questions: What was the main reason for not following up? What is your current vision function? How many glaucoma drops are you using? Do you have any eye pain? Are you overall satisfied with the outcome of the treatment?

Statistical methods

Data analysis was performed using Statistica 13.1 (Tulsa, Oklahoma, United States). The frequency of observations described categorical variables. Continuous variables were described as mean with standard deviation (SD) or median with range (minimum-maximum). Friedman test and Wilcoxon signed-rank test were used to compare data measured on an ordinal scale and continuous variables with non-normal distribution. Evaluation of data normality was performed using the Shapiro-Wilk test. Welch's t-test for unequal variances was used for IOP between pain versus no-pain group comparison. Categorical variables of the relationship between neovascularization stage and type of intervention were compared using the χ^2 test with odds ratio (OR) measurement. Kaplan-Meier curve and log-rank test were used for success analysis. P-values < 0.05 were considered significant.

An earlier version of this article can be found on medRxiv (doi: <https://doi.org/10.1101/2020.01.19.20017889>)

Results

All 77 patients (45 male, 32 female, mean 73.6 ± 12.2 years, range 29–91 years) completed a one-year follow-up and were included in the retrospective analysis (Figure 1). Conditions that lead

Figure 1. Flow chart. Eyes with no light perception and patients with a history of glaucoma other than neovascular glaucoma were excluded. *Telephone survey with all patients lost to follow-up.

to NVG included CRVO 41.6% (32/77), PDR 35.1% (27/77), CRAO 19.5% (15/77), and ocular ischemic syndrome 3.9% (3/77)³⁷ (Table 1).

The most common cardiovascular risk factor was arterial hypertension 87.0% (67/77), followed by hyperlipidemia 67.5% (52/77), diabetes mellitus 59.7% (46/77), and smoking 11.7% (9/77). While one patient did not have any cardiovascular risk factors, 24.7% (19/77) had at least one risk factor, and 74.0% (57/77) had multiple risk factors.

The mean body mass index (BMI kg/m²) for the study group was 28.7±5.0 (underweight ≤ 18.5, normal weight = 18.5–24.9, overweight = 25–29.9, obesity ≥ 30³⁸). 1.3% (1/77) were

underweight, 24.7% (19/77) had a normal weight, 40.3% were overweight (31/77) and 33.8% (26/77) obese.

Mean logMAR BCVA was 1.9±0.7 at baseline, 1.7±0.8 at one month, 1.8±0.8 at three months, 1.8±0.8 at six months, and 1.8±0.8 at 12 months ($p=0.47$, Figure 2). At baseline, 35.1% (27/77) of patients and at 12 months, 45.5% (35/77) of patients had an ambulatory visual acuity ($\geq$ logMAR 1.7), respectively, but was not statistically significant ($p=0.0931$). One eye worsened from LP to NLP at one week, three eyes at six months, and three eyes at 12 months.

IOP decreased significantly from 46.3±10.1 mmHg at baseline to 21.4±10.9 mmHg at one month, 18.6±10.7 mmHg at three months, 15.1±7.6 mmHg at six months, and 14.5±7.9 mmHg at 12 months ($p<0.001$; Figure 3). At one-year follow-up, 89.6% ($n=69$) of patients had an IOP $\leq$ 21 mmHg. IOP $\leq$ 5 mmHg was found in 7.8% ($n=6$) and tolerated without complications. 96.1% ($n=74$) presented at baseline with IOP $\geq$ 30 mmHg. The number of glaucoma medication decreased from 4.7±1.3 at baseline to 1.9±1.9 at one month, 1.8±1.7 at three months, 1.8±1.5 at six months, and 1.8±1.8 ($p<0.001$; Figure 4) at 12 months.

While 32.5% ($n=29$) of patients complained of ocular pain at baseline (VAPS: 6.0±1.8), all patients were without pain at all follow-up visits. Patients with pain had a significantly higher baseline IOP of 49.9±9.0 mmHg than patients without pain 44.1±10.3 mmHg ($p<0.01$).

Early postoperative complications (day 1 to four weeks) included intraocular fibrin 67.5% (52/77), hyphema 20.8% (16/77), choroidal detachment 16.9% (13/77), and corneal erosion 14.3% (11/77). Late postoperative complications (> 1 months) included retinal detachment in 3.9% (3/77) and painless phthisis in 3.9% (3/77) (Table 2).

At the one-year follow-up, surgical intervention was required in 16.9% (22/77) eyes. Of these eyes, 63.6% (14/22) received vitrectomy, 22.7% (5/22) a Baerveldt glaucoma drainage implant, 4.5% (1/22) a trabeculectomy with mitomycin C and 4.5% (1/22) a keratoplasty. One painful and blind eye needed enucleation.

Repeat transscleral cyclophotocoagulation was performed in 11.6% (15/77). 3.9% (5/77) of patients with a mean BCVA 1.1±0.3 logMAR received an additional 4.0±0.8 anti-VEGF injections.

At baseline, 11.7% (9/77) had an anterior chamber neovascularization stage (rubeosis (R) stage) of 2, 33.8% (26/77) stage 3 and 54.5% (42/77) stage 4. The combined average stage was 3.4±0.7 (range 2–4). Patients with stage 4 needed significantly more major interventions compared with stage 3 (OR 25.0, 95% CI 3.09–201.7, $p=0.003$) and stage 2 (OR 19.0, 95% CI 1.03–347.3, $p=0.047$). There was no statistically significant difference between the number of interventions required at stage 2 and stage 3 (OR 0.89, 95% CI 0.03–23.9, $p=0.9471$). Kaplan-Meier analysis showed a probability of success of 65% at one-year follow-up (Figure 5).

Table 1. Demographic characteristics of neovascular glaucoma patients.

Variables	n = 77
Age (years)	73.6±12.2 (range 29–91)
Gender	n (%)
Female	32 (41.6)
Male	45 (58.4)
Laterality	n (%)
Right	34 (44.2)
Left	43 (55.8)
Diagnosis	n (%)
CRAO	15 (19.5)
CRVO	32 (41.6)
PDR	27 (35.1)
OIS	3 (3.9)
BMI (kg/m ²)	n (%)
<18.5	1 (1.3)
18.5–24.9	19 (24.7)
25–29.9	31 (40.3)
30–34.9	19 (24.7)
>35	7 (9.1)
R-stadium	n (%)
Stadium 1	0 (0)
Stadium 2	9 (11.7)
Stadium 3	26 (33.8)
Stadium 4	42 (54.5)

BMI, body mass index; CRAO, central retinal artery occlusion; CRVO, central retinal vein occlusion; PDR, proliferative diabetic retinopathy; OIS, ocular ischemic syndrome.

Figure 2. Visual acuity during follow-up (mean ± SD) ($p=0.47$).

Figure 3. Intraocular pressure (IOP) during follow-up (mean ± SD) ($p<0.001$).

Figure 4. Number of glaucoma medication during follow-up (mean ± SD) ($p < 0.001$).

Table 2. Early postoperative inflammation and postoperative complications.

Complications	n (%)
Early inflammation/complications	
Extensive fibrin	52 (67.5)
Hyphema	16 (20.8)
Choroidal swelling	13 (16.9)
Corneal erosion	11 (14.3)
Late complications	n (%)
Retinal detachment	3 (3.9)
Phthisis	3 (3.9)

Lost to follow-up

21 patients were lost to follow-up. 10 patients died during the one-year follow-up period. All 21 patients lost to follow-up completed a telephone survey. The main reasons for missed visits were general health issues in 52.4% (11/21), long-distance to our clinic 38.1% (8/21), and family-related reasons in 9.5% (2/21). 57.1% (12/21) of patients had retained at least ambulatory vision. 71.4% (15/21) used 1.7 ± 1.2 glaucoma eye drops. 95.2% (21/22) reported overall satisfaction with the treatment. All patients were pain-free.

Discussion

By 1871, NVG was known as “glaucoma haemorrhagicum et apoplecticum” and feared as a consequence of ischemia that quickly led to enucleation due to “hefty ciliary neuralgia”³⁹. In 1963, using improved equipment, Weiss *et al.* found that emerging neovascularization and fibrovascular membranes of the iris and the angle could be observed well before the onset of advanced NVG⁴⁰, hinting at a window to initiate treatment. Today, the ability to detect neovascularization early is complemented by improved interventions that address both the underlying pathology and elevated IOP. However, these interventions need to be implemented during the early stages of the disease because NVG continues to have a rapid evolution and a poor prognosis for both the eye and the patient¹². One study showed that the expected lifespan of patients with NVG decreased by 52% compared to an age-correlated normal population, corresponding to a loss of 6.5 years. In diabetics with NVG, the lifespan was reduced even more by 72%¹². In our study, 74% (57/77) of patients had multiple cardiovascular risk factors and were overweight or obese. During follow-up, ten patients died. The high mortality rate is a reminder that any treatment strategy of NVG should aim at keeping the number of necessary follow-up visits and additional interventions at a minimum. We tried to address this need by combining several interventions in a single surgical session.

Retinal ischemia is the primary cause of NVG^{10,41}. Accordingly, PRP is the standard of care to reduce posterior pole oxygen demand and angiogenic drive while vitrectomy is performed

Figure 5. Kaplan-Meier univariate estimates of the probability of success: intraocular pressure (IOP) ≤ 21 mmHg or IOP reduction $\geq 30\%$ from baseline, with or without glaucoma medication, without vision loss.

to increase the partial pressure of vitreous oxygen^{42,43}. We performed lens extraction, pars plana vitrectomy, and endoscopic PRP because of significant media opacities and because endoscopic laser through the pars plana approach facilitates the delivery of 360° near-confluent peripheral retinal laser treatment out to the ora serrata. In our clinical experience, even relatively small areas of retinal ischemia may cause further NVG progression. Therefore, we took care to apply 360° PRP to near-confluence up to the ora serrata. Such extensive treatment would be challenging or impossible using standard PRP with an indirect ophthalmoscope or at the slit lamp.

In the healthy eye, the vitreous body and the iris-lens diaphragm form a relative diffusion barrier that maintains a higher oxygen partial pressure in the posterior chamber than the vitreous overlying the posterior pole. Concurrently, it reduces the diffusion of angiogenic mediators. Recreating a relative diffusion barrier after vitrectomy⁴⁴ is beneficial and reduces NVI occurrence⁴⁵. A relative barrier can be achieved with silicone oil⁴⁶ that reduces the incidence of NVG^{46,47}. Following this concept, Bartz-Schmidt *et al.* treated 32 NVG patients with pars plana vitrectomy, retinal, and ciliary body photocoagulation, and

silicone oil tamponade as eyes were left aphakic. This approach controlled IOP (defined as an IOP between 8 and 21 mmHg) in 72% of patients for at least one year³⁰. In our study we achieved an IOP control in 77.9% and all eyes were pseudophakic and without silicone oil at the conclusion of the surgery, thereby suggesting that silicone oil as a diffusion barrier may not be necessary³⁰.

Our success rate of 65%, defined as an IOP < 22 mmHg, with or without glaucoma medication and without vision loss after a one-year follow-up, is similar to success rates reported for glaucoma drainage devices, which range from 62% to 66.7%^{24,48–50}. One study reported a 73% success rate in 38 eyes that received a glaucoma drainage device and had relatively few postoperative complications⁵¹. However, this report is the exception as others have found^{24,48–50}. Our integrative surgical approach avoided tube-specific complications (e.g., tube exposure, retraction, corneal touch, obstruction), ranging from 13% to 26% in NVG over five years^{24,48–51}. It delivers both retina and glaucoma treatment in a single surgical session and reduces the patient and health care system burden by simplifying postoperative care and follow-up. Our telephone survey with all patients lost to follow-up

revealed that the main reasons for missed visits were other (general) health issues in 52.4% and long distance to the clinic in 38.1% but a high subjective satisfaction rate.

Patients with stage 4 anterior chamber neovascularization needed significantly more major interventions than stage 3 or stage 2, but there was a difference between stage 2 and stage 3. This finding suggests that early and comprehensive treatment may be more beneficial than a stepwise treatment strategy.

It is worth noting that IOP reduction can also be achieved without cyclodestruction applying only pars plana vitrectomy, lensectomy with a preserved anterior capsule, and panretinal endophotocoagulation as reported by Kinoshita *et al.*³¹. However, this study included only 13 eyes with a lower mean preoperative IOP of 29 mmHg as in our study. By contrast, other studies that only used anti-VEGF agents as primary treatment^{28,52} reported failure rates up to 88%. Anti-VEGF agents may be best used as an adjuvant treatment²⁹. Consistent with our findings, a study that used pars plana vitrectomy, endoscopic peripheral panretinal photocoagulation, and endocyclophotocoagulation (ECP) also achieved an IOP reduction which was more effective than panretinal photocoagulation, intravitreal bevacizumab, pars plana vitrectomy, and trabeculectomy with mitomycin C or Ahmed valve placement. However, the authors reported a higher phthisis rate of 7.4%⁵³.

Because of the underlying ocular disease, visual function remained low in most eyes in our study.

There are limitations to our study. Because the integrative surgical approach described here was the primary practice pattern, there was no control group. This limited us to an intragroup comparison of before versus after treatment data. As a retrospective study, it can only inform on future prospective studies' parameters and design and help formulate, but not answer, hypotheses about associations between treatment and outcomes.

In conclusion, this study shows that NVG can be controlled in most cases by an integrative surgical approach delivered in a single surgical session that combines transscleral cyclophotocoagulation, cataract removal, pars plana vitrectomy, near-confluent full-scatter panretinal photocoagulation, and intravitreal bevacizumab. Patients with advanced iris neovascularization required significantly more additional interventions. The described approach lowered IOP significantly, reduced the number of glaucoma medications, and controlled pain.

Data availability

Underlying data

Open Science Framework: Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma — a retrospective interventional case series. <https://doi.org/10.17605/OSF.IO/QTCGV37>.

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

References

- Karaman S, Leppänen VM, Alitalo K: **Vascular endothelial growth factor signaling in development and disease.** *Development.* 2018; **145**(14): dev151019.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Liao N, Li C, Jiang H, *et al.*: **Neovascular glaucoma: a retrospective review from a tertiary center in China.** *BMC Ophthalmol.* 2016; **16**(1): 14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Drobec P: **Das hämorrhagische Sekundärglaukom.** *Klinische Monatsblätter für Augenheilkunde.* 1982; **180**(02): 138–40.
- Mocanu C, Barăscu D, Marinescu F, *et al.*: **[Neovascular glaucoma—retrospective study].** *Oftalmologia.* 2005; **49**(4): 58–65.
[PubMed Abstract](#)
- Gesundheitsberichterstattung des Bundes (GBE Bund): **Diagnosedaten der Krankenhäuser ab 2000 (Eckdaten der vollstationären Patienten und Patientinnen).**
[Reference Source](#)
- Natural History and Clinical Management of Central Retinal Vein Occlusion.** The Central Vein Occlusion Study Group. *Arch Ophthalmol.* 1997; **115**(4): 486–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nielsen NV: **The prevalence of glaucoma and ocular hypertension in type 1 and 2 diabetes mellitus.** *Acta Ophthalmol (Copenh).* 1983; **61**(4): 662–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rudkin AK, Lee AW, Chen CS: **Ocular neovascularization following central retinal artery occlusion: prevalence and timing of onset.** *Eur J Ophthalmol.* 2010; **20**(6): 1042–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brown GC, Magargal LE, Schachat A, *et al.*: **Neovascular glaucoma. Etiologic considerations.** *Ophthalmology.* 1984; **91**(4): 315–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Havens SJ, Gulati V: **Neovascular Glaucoma.** *Dev Ophthalmol.* 2016; **55**: 196–204.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Setlur VJ, Parikh JG, Rao NA: **Changing causes of enucleation over the past 60 years.** *Graefes Arch Clin Exp Ophthalmol.* 2010; **248**(4): 593–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Blanc JP, Molteni ACB, Fuller JR, *et al.*: **Life expectancy of patients with neovascular glaucoma drained by Molteni implants.** *Clin Exp Ophthalmol.* 2004; **32**(4): 360–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Miller JW, Adamis AP, Shima DT, *et al.*: **Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.** *Am J Pathol.* 1994; **145**(3): 574–84.
[PubMed Abstract](#) | [Free Full Text](#)
- Penn JS, Madan A, Caldwell RB, *et al.*: **Vascular endothelial growth factor in eye disease.** *Prog Retin Eye Res.* 2008; **27**(4): 331–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ford KM, Saint-Geniez M, Walshe T, *et al.*: **Expression and role of VEGF in the adult retinal pigment epithelium.** *Invest Ophthalmol Vis Sci.* 2011; **52**(13): 9478–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Vempati P, Popel AS, Mac Gabhann F: **Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.** *Cytokine Growth Factor Rev.* 2014; **25**(1): 1–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Loewen N, Chen J, Dudley VJ, *et al.*: **Genomic response of hypoxic Müller cells involves the very low density lipoprotein receptor as part of an angiogenic network.** *Exp Eye Res.* 2009; **88**(5): 928–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schofield CJ, Ratcliffe PJ: **Oxygen sensing by HIF hydroxylases.** *Nat Rev Mol Cell*

- Biol.* 2004; **5**(5): 343–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Tsuzuki Y, Fukumura D, Oosthuysen B, *et al.*: **Vascular Endothelial Growth Factor (VEGF) Modulation by Targeting Hypoxia-inducible Factor-1 α → Hypoxia Response Element → VEGF Cascade Differentially Regulates Vascular Response and Growth Rate in Tumors.** *Cancer Res.* 2000.
[Reference Source](#)
 20. Schlote T, Derse M, Rassmann K, *et al.*: **Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma.** *J Glaucoma.* 2001; **10**(4): 294–301.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Delgado MF, Dickens CJ, Iwach AG, *et al.*: **Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma.** *Ophthalmology.* 2003; **110**(5): 895–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Oguri A, Takahashi E, Tomita G, *et al.*: **Transscleral cyclophotocoagulation with the diode laser for neovascular glaucoma.** *Ophthalmic Surg Lasers.* 1998; **29**(9): 722–7.
[PubMed Abstract](#)
 23. Shchomak Z, Cordeiro Sousa D, Leal I, *et al.*: **Surgical treatment of neovascular glaucoma: a systematic review and meta-analysis.** *Graefes Arch Clin Exp Ophthalmol.* 2019; **257**(6): 1079–89.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Zhou M, Xu X, Zhang X, *et al.*: **Clinical Outcomes of Ahmed Glaucoma Valve Implantation With or Without Intravitreal Bevacizumab Pretreatment for Neovascular Glaucoma: A Systematic Review and Meta-Analysis.** *J Glaucoma.* 2016; **25**(7): 551–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Chuang LH, Wang NK, Chen YP, *et al.*: **Vitrectomy and panretinal photocoagulation reduces the occurrence of neovascular glaucoma in central retinal vein occlusion with vitreous hemorrhage.** *Retina.* 2013; **33**(4): 798–802.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Budzynski E, Smith JH, Bryar P, *et al.*: **Effects of photocoagulation on intraretinal PO₂ in cat.** *Invest Ophthalmol Vis Sci.* 2008; **49**(1): 380–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Yazdani S, Hendi K, Pakravan M: **Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.** *J Glaucoma.* 2007; **16**(5): 437–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Lüke J, Nassar K, Lüke M, *et al.*: **Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma—results from a prospective interventional case series.** *Graefes Arch Clin Exp Ophthalmol.* 2013; **251**(10): 2403–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Olmos LC, Sayed MS, Moraczewski AL, *et al.*: **Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.** *Eye (Lond).* 2016; **30**(3): 463–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Bartz-Schmidt KU, Thumann G, Psichias A, *et al.*: **Pars plana vitrectomy, endolaser coagulation of the retina and the ciliary body combined with silicone oil endotamponade in the treatment of uncontrolled neovascular glaucoma.** *Graefes Arch Clin Exp Ophthalmol.* 1999; **237**(12): 969–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Kinoshita N, Ota A, Toyoda F, *et al.*: **Surgical results of pars plana vitrectomy combined with pars plana lensectomy with anterior capsule preservation, endophotocoagulation, and silicon oil tamponade for neovascular glaucoma.** *Clin Ophthalmol.* 2011; **5**: 1777–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Weiss DI, Gold D: **Neofibrovacularization of iris and anterior chamber angle: a clinical classification.** *Ann Ophthalmol.* 1978; **10**(4): 488–91.
[PubMed Abstract](#)
 33. Abbas A, Agrawal P, King AJ: **Exploring literature-based definitions of hypotony following glaucoma filtration surgery and the impact on clinical outcomes.** *Acta Ophthalmol.* 2018; **96**(3): e285–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Tan LT, Isa H, Lightman S, *et al.*: **Prevalence and causes of phthisis bulbi in a uveitis clinic.** *Acta Ophthalmol.* 2012; **90**(5): e417–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Shaarawy TM, Sherwood MB, Grehn F: **WGA Guidelines on Design and Reporting of Glaucoma Surgical Trials.** Kugler Publications; 2009; 83.
[Reference Source](#)
 36. Bach M, Schulze-Bonsel K, Feltgen N, *et al.*: **Author response: numerical imputation for low vision states [electronic letter].** *Invest Ophthalmol Vis Sci.* 2007; **26**.
 37. Strzalkowski P, Strzalkowska A, Loewen N: **Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma — a retrospective interventional case series.** 2020.
<http://www.doi.org/10.17605/OSF.IO/QTCGV>
 38. **Calculate Your BMI - Standard BMI Calculator [Internet].** [cited 2020 Sep 13].
[Reference Source](#)
 39. Pagenstecher H: **Mittheilungen aus der Augenheilkunde zu Wiesbaden: Beiträge zur Lehre vom hämorrhagischen Glaukom.** *Albrecht von Graefes Archiv für Ophthalmologie.* 1871; **17**(2): 98–130.
 40. Weiss DI, Shaffer RN, Nehrenberg TR: **Neovascular Glaucoma complicating carotid-cavernous fistula.** *Arch Ophthalmol.* 1963; **69**(3): 304–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Stefánsson E: **Ocular oxygenation and the treatment of diabetic retinopathy.** *Surv Ophthalmol.* 2006; **51**(4): 364–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Stefánsson E, Landers MB 3rd, Wolbarsht ML: **Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy.** *Trans Am Ophthalmol Soc.* 1981; **79**: 307–34.
[PubMed Abstract](#) | [Free Full Text](#)
 43. Simpson ARH, Dowell NG, Jackson TL, *et al.*: **Measuring the effect of pars plana vitrectomy on vitreous oxygenation using magnetic resonance imaging.** *Invest Ophthalmol Vis Sci.* 2013; **54**(3): 2028–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Stefánsson E, Landers MB 3rd, Wolbarsht ML: **Vitrectomy, lensectomy, and ocular oxygenation.** *Retina.* 1982; **2**(3): 159–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Rice TA, Michels RG, Maguire MG, *et al.*: **The effect of lensectomy on the incidence of iris neovascularization and neovascular glaucoma after vitrectomy for diabetic retinopathy.** *Am J Ophthalmol.* 1983; **95**(1): 1–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. de Juan EJ Jr, Hardy M, Hatchell DL, *et al.*: **The effect of intraocular silicone oil on anterior chamber oxygen pressure in cats.** *Arch Ophthalmol.* 1986; **104**(7): 1063–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Rinkoff JS, de Juan EJ Jr, McCuen BW: **Silicone oil for retinal detachment with advanced proliferative vitreoretinopathy following failed vitrectomy for proliferative diabetic retinopathy.** *Am J Ophthalmol.* 1986; **101**(2): 181–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Yalvac IS, Eksioğlu U, Satana B, *et al.*: **Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma.** *Eye (Lond).* 2007; **21**(1): 65–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Every SG, Molteno ACB, Bevin TH, *et al.*: **Long-term results of Molteno implant insertion in cases of neovascular glaucoma.** *Arch Ophthalmol.* 2006; **124**(3): 355–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Xie Z, Liu H, Du M, *et al.*: **Efficacy of Ahmed Glaucoma Valve Implantation on Neovascular Glaucoma.** *Int J Med Sci.* 2019; **16**(10): 1371–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Netland PA, Ishida K, Boyle JW: **The Ahmed Glaucoma Valve in patients with and without neovascular glaucoma.** *J Glaucoma.* 2010; **19**(9): 581–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Yazdani S, Hendi K, Pakravan M, *et al.*: **Intravitreal Bevacizumab for Neovascular Glaucoma: A Randomized Controlled Trial.** *J Glaucoma.* 2009; **18**(8): 632–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Marra KV, Wagley S, Omar A, *et al.*: **Case-matched comparison of vitrectomy, peripheral retinal endolaser, and endocyclophotocoagulation versus standard care in neovascular glaucoma.** *Retina.* 2015; **35**(6): 1072–83.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 01 December 2020

<https://doi.org/10.5256/f1000research.29684.r75197>

© 2020 Dithmar S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stefan Dithmar

Department of Ophthalmology, HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany

The authors present a very interesting observational study on the therapy of neovascularization glaucoma. The treatment of this clinical entity is difficult and often unsatisfactory. The authors report on a convincing surgical approach and present retrospective results in a relatively large patient group. The presentation of the results is good and the manuscript is well written.

Taking into account the reviewer report by Andrew W. Eller, I have no further comments to make.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Retina research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 20 November 2020

<https://doi.org/10.5256/f1000research.29684.r73906>

© 2020 Eller A et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Andrew W. Eller

Retina Service, Department of Ophthalmology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA

Saloni Kapoor

University of Pittsburgh Medical Center, Pittsburgh, USA

In this study Dr Strzalkowski *et al.* provide a retrospective observational analysis of a single center's experience with aggressive upfront treatment of neovascular glaucoma (NVG) with combined vitrectomy, near confluent pan retinal endolaser, bevacizumab and transscleral cyclophotocoagulation.

The authors hypothesize that upfront combined treatment would improve outcomes in terms of IOP, antiglaucoma medications, pain, necessity of further surgeries and help reduce follow-up visits. They report baseline characteristics and one-year outcomes for 77 patients with neovascular glaucoma that underwent the combined procedure. We congratulate them on implementing a success strategy in treating these complex cases. Often patients with NVG have disastrous outcomes with poorly controlled IOP and significant loss of vision. In this series, a number of patients were able to maintain reasonable vision. It can often be difficult to "titrate" treatment of IOP, often resulting in hypotony. There were three patients with phthisis bulbi and another six with hypotony for a total of nine or 11.7%. Three patients developed retinal detachment. Perhaps these were the same three patients who developed phthisis bulbi.

The major drawback of this study is the lack of alternate treatments for randomization. This limits our ability to draw any conclusions about optimal management strategies and only hypotheses can be generated. This is appropriately acknowledged by the authors who are careful not to overstate their conclusions.

The authors seemed to have correlated surgical success with the stage of iris neovascularization. In other words, there were more surgical interventions with stage 4, then stages 2 or 3. It is the experience of this reviewer that one can correlate treatment success of NVG with presenting IOP and the immediate response of IOP to medical therapy. In clinic, if the initial IOP is less than 40 mmHg and medical treatment can reduce the IOP into the low 20's, these patients can often be treated with an initial injection of an anti-VEGF medication, followed by PRP laser. In the long term, any residual glaucoma can usually be treated with medical therapy alone. Those patients presenting with an IOP greater than 40 mmHg, and not responding to medical therapy will require

more aggressive treatment. If the visual potential is reasonable, this treatment may include anti-VEGF, PRP laser (with vitrectomy if visualization of the retina is poor), and glaucoma surgery. If the visual potential is very poor, then not invasive glaucoma treatment such as transscleral CPC) is advised. Using their data, are the authors able to confirm our observations regarding treatment of NVG.

As the authors have stated, there are a number of different underlying causes of neovascular glaucoma and they have been combined in this series. This is a fairly large series and we question whether the severity of the NVG and response to treatment may have differed according to the underlying pathology. For example, the iris neovascularization and glaucoma in central retinal vein occlusions (CRVO) tends to progress more rapidly than seen with diabetic retinopathy. Once the retinal ischemia has been addressed in CRVO, it seems these eyes are more likely to develop hypotony. What was the experience of the authors in this study?

The authors cite two studies from the mid-1980's when the use of silicone oil was very much in its early stages of clinical usage. At that time, it was felt that silicone oil reduced or perhaps prevented the flow of VEGF into the anterior chamber and therefore decreased the risk of iris neovascularization and glaucoma. We believe this theory has been discounted as we know that there is a flow of aqueous humor from the posterior segment into the anterior chamber. Retinal detachment alone increases VEGF production and it occurs in cases of proliferative diabetic retinopathy there can be an even more profound angiogenic effect. An alternative explanation for this observation is that silicone oil improves the outcome in these eyes by simply improving the chances for retinal re-attachment.

In the Introduction, the authors hypothesize that the combined approach would help decrease outpatient visits. This is again emphasized in the Discussion where authors report that patients with neovascular glaucoma have significant comorbidities and lower life expectancy and would therefore benefit from decreased outpatient visits. The counter-argument to be made is that combined aggressive surgical intervention would increase risk of complications and require closer monitoring. No data is provided on the number of follow up visits. Consider adding to results if available. The authors could consider performing a regression analysis to determine which baseline characteristics predicted success with this combined technique. This analysis will help identify patients in whom this technique would be most helpful. It could also show when this technique may be more aggressive than necessary in some cases, and could be more aggressive in others when the addition of a glaucoma drainage device may be beneficial.

Specific comments for revision:

1. In the Introduction, second paragraph, suggest following change. "In 1994, Miller *et al.* showed that laser occlusion of all branch retinal veins in a primate could lead to CRVO and subsequent retinal ischemia."
2. In the Results, consider rephrasing "arterial hypertension" to hypertension as this is the currently accepted terminology.
3. In Table 1 – consider rephrasing "R stadium" to read "NVI Stage" or Weiss and Gold Rubeosis grading to ensure clarity.
4. In the Discussion, it would be beneficial to see outcomes with staged surgical approach (Incisional surgical management with trabeculectomy/tubes, followed by cryotherapy if poor response) from existing literature to enable some comparison with the combined approach reported in this manuscript.

5. In the Discussion, the authors state “Patients with stage 4 anterior chamber neovascularization needed significantly more major interventions than stage 3 or stage 2, but there was a difference between stage 2 and stage 3”. The data reports NO significant difference between stage 2 and 3. Please clarify.

Overall, a well-organized manuscript with a practical approach to the treatment of neovascular glaucoma with novel data.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Ophthalmology, Vitreo-Retinal Diseases and Surgery

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 23 Jan 2021

Piotr Strzalkowski, University Hospital Würzburg, Germany

Dear Reviewers,

We are grateful for the opportunity to improve our manuscript. We appreciate the helpful comments and have provided our replies below. We trust that we were able to address the concerns that were raised.

Thank you,

Piotr Strzalkowski

Reviewers' comments:

Reviewer #1 ("R1" in the following): There were three patients with phthisis bulbi and another six with hypotony for a total of nine or 11.7%. Three patients developed retinal detachment. Perhaps these were the same three patients who developed phthisis bulbi.

Authors: That is exactly correct. We appreciate the thoughtful analysis. All three patients with retinal detachment also developed phthisis bulbi. We added this important information to our manuscript.

R1, 1: As the authors have stated, there are a number of different underlying causes of neovascular glaucoma and they have been combined in this series. This is a fairly large series and we question whether the severity of the NVG and response to treatment may have differed according to the underlying pathology. For example, the iris neovascularization and glaucoma in central retinal vein occlusions (CRVO) tends to progress more rapidly than seen with diabetic retinopathy. Once the retinal ischemia has been addressed in CRVO, it seems these eyes are more likely to develop hypotony. What was the experience of the authors in this study?

Authors: Thank you for sharing your clinical experience. Based on our data we could not find a statistical significant difference in postoperative IOP or hypotony between CRVO and PDR patients.

R1, 2: No data is provided on the number of follow up visits. Consider adding to results if available.

Authors: Information about the number of follow up visits is provided in section "study design": All patients were treated at the University Eye Hospital in Würzburg, Germany. The combined intervention was part of routine patient care at our clinic and all patients with decompensated neovascular glaucoma and preserved visual function received this intervention. BCVA, intraocular pressure (IOP, mmHg), the number of glaucoma medication, visual analog pain scale (VAPS, 0-10) was recorded at baseline and at follow-up visits at one, three, six, and 12 months as part of routine care.

R1, 3: The authors could consider performing a regression analysis to determine which baseline characteristics predicted success with this combined technique. This analysis will help identify patients in whom this technique would be most helpful.

Authors: Regression analysis was not included in this study on purpose because this analysis is part of our ongoing study.

R1, Specific Comments:

- In the Introduction, second paragraph, suggest following change. "In 1994, Miller et al. showed that laser occlusion of all branch retinal veins in a primate could lead to CRVO and subsequent retinal ischemia."
- In the Results, consider rephrasing "arterial hypertension" to hypertension as this is the currently accepted terminology.
- In Table 1 – consider rephrasing "R stadium" to read "NVI Stage" or Weiss and Gold Rubeosis grading to ensure clarity.
- In the Discussion, it would be beneficial to see outcomes with staged surgical

approach (Incisional surgical management with trabeculectomy/tubes, followed by cryotherapy if poor response) from existing literature to enable some comparison with the combined approach reported in this manuscript.

- In the Discussion, the authors state "Patients with stage 4 anterior chamber neovascularization needed significantly more major interventions than stage 3 or stage 2, but there was a difference between stage 2 and stage 3". The data reports NO significant difference between stage 2 and 3. Please clarify.

Authors: We have changed the manuscript to include these suggestions.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research